ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

mRNA Therapeutics and Global Markets to 2030, Profiles of Leading Companies - Moderna, Pfizer, BioNTech, Merck, and Sanofi - ResearchAndMarkets.com

The "mRNA: Therapeutics and Global Markets" report has been added to ResearchAndMarkets.com's offering.

The global market for mRNA therapeutics was valued at $7.71 billion in 2025 and is forecast to remain stable or slightly decline to $7.69 billion by the end of 2030, at a compound annual growth rate (CAGR) of -0.04% during the forecast period of 2025 to 2030.

The report analyzes the global market for mRNA therapeutics. It includes global revenue ($ millions) for the base year of 2024, estimated data for 2025 and projected compound annual growth rates (CAGRs) through 2030. The report examines the different types of mRNA and their applications for therapeutic use. It also focuses on mRNA patents and clinical trials and examines the trends affecting the market during the forecast period. The report profiles the leading companies and their strategic alliances and partnerships.

Therapies using messenger ribonucleic acid, or mRNA, have immense potential for treating chronic diseases. Vaccines incorporating mRNA provide several advantages over DNA vaccines in manufacturing, distribution and safety. There is a demand for vaccines and treatments using mRNA because of their encouraging results in human clinical trials. The market is expanding due to increased clinical trials and the global proliferation of stem cell therapies. Governments, academic institutions and biotech and pharma companies are concentrating on detecting infectious and rare diseases. The global market for mRNA therapeutics market presents a multibillion-dollar opportunity for vaccines and other therapies.

COVID-19 mRNA-based vaccines are currently available, and research continues to find new methods for preventing and treating infections and illnesses. Essential for many bodily functions, mRNA instructs the body's cells to produce proteins. Essentially, mRNA participates in biological processes within our bodies to potentially treat diseases and stop infections.

Report Includes

  • 19 data tables and 71 additional tables
  • An overview and analysis of the global markets for messenger RNA (mRNA)-based therapeutics
  • Analyses of the global market trends, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
  • Estimates of the size and revenue prospects for the global mRNA market, along with a market share analysis by disease type, indication, and region
  • Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations and the impacts of macroeconomic variables
  • Insights derived from Porter's Five Forces model, global supply chain and PESTLE analyses
  • Patent analysis, featuring key granted and published patents
  • Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings and consumer attitudes
  • Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
  • Profiles of the leading companies, including Moderna Inc., Pfizer Inc., BioNTech SE, Merck & Co., and Sanofi

Company Profiles

  • Arcturus Therapeutics Inc.
  • Astrazeneca
  • Biocina
  • Biontech Se
  • Curevac Se
  • Ethris Gmbh
  • Gennova Biopharmaceuticals Ltd.
  • GSK Plc.
  • Immorna (Hangzhou) Biotechnology Co. Ltd.
  • Merck & Co. Inc.
  • Moderna Inc.
  • Nutcracker Therapeutics Inc.
  • Pfizer Inc.
  • Providence Therapeutics
  • Sanofi
  • Strand Therapeutics Inc.

Key Topics Covered:

Chapter 1 Executive Summary

  • Market Outlook
  • Scope of Report
  • Market Summary
  • Market Growth Factors
  • Emerging Technologies
  • COVID mRNA Vaccines
  • Regional Analysis
  • Conclusion

Chapter 2 Market Overview

  • Technology Background
  • Evolution of RNA Therapeutics
  • DNA Therapeutics vs. RNA Therapeutics
  • RNA Therapeutics
  • mRNA as Therapeutics
  • Regulatory Agency-Approved mRNA Vaccines
  • Porter's Five Forces Analysis
  • Impact of U.S. Tariffs on the mRNA Therapeutics Market
  • Conclusion

Chapter 3 Market Dynamics

  • Overview
  • Market Drivers
  • Rising Numbers of Pandemics and Epidemics
  • Awareness of the Need for Vaccinations
  • Investments in mRNA Therapeutics Research
  • Market Restraints
  • Limitations of mRNA Vaccines
  • Production and Logistical Hurdles
  • Market Opportunities
  • Personalized Cancer Vaccines
  • Potential of mRNA Drugs to Treat Various Diseases

Chapter 4 Regulatory Landscape

  • Regulatory Scenario
  • Overview of Regulatory Bodies
  • Guidelines and Standards for mRNA Vaccines
  • Preclinical and Clinical Evaluation
  • Manufacturing and Post-Marketing Surveillance
  • Continual Monitoring and Risk Management

Chapter 5 Pipeline and Clinical Trial Analysis

  • Takeaways
  • mRNA Vaccines

Chapter 6 Market Segmentation Analysis

  • Segmentation Breakdown
  • Market Breakdown by Disease Type
  • Takeaways
  • COVID mRNA Vaccines
  • Non-COVID mRNA Vaccines and Therapeutics
  • Market Breakdown by Indication
  • Cancer
  • Infectious Diseases
  • Rare Diseases
  • Others
  • Geographic Breakdown
  • Market Breakdown, by Region
  • Takeaways
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Chapter 7 Emerging Technologies and Developments

  • Emerging Technologies in mRNA Therapeutics
  • Nanoparticles
  • Modified mRNA
  • Automated mRNA Synthesis Kits
  • Bio Platforms
  • Artificial Intelligence
  • AI Developments at mRNA Therapeutics Companies

Chapter 8 Patent Analysis

  • Takeaways
  • mRNA Publications
  • List of Patents

Chapter 9 Sustainability in the mRNA Therapeutics Industry: An ESG Perspective

  • Sustainability in the mRNA Therapeutics Industry
  • ESG Risk Ratings
  • ESG Performance Analysis
  • Environmental Performance
  • Social Performance
  • Governance Performance
  • Concluding Remarks

Chapter 10 Competitive Intelligence

  • Takeaways
  • Leading Companies in the mRNA Therapeutics Market, 2024
  • Strategic Analysis
  • Collaborations and Partnerships
  • Regulatory Approvals
  • Clinical Trials Data
  • Funding and Grants

Chapter 11 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/3vsuvx

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com



For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+1.37 (0.56%)
AAPL  268.47
-1.30 (-0.48%)
AMD  233.54
-4.16 (-1.75%)
BAC  53.20
-0.09 (-0.17%)
GOOG  279.70
-5.64 (-1.98%)
META  621.71
+2.77 (0.45%)
MSFT  496.82
-0.28 (-0.06%)
NVDA  188.15
+0.07 (0.04%)
ORCL  239.26
-4.54 (-1.86%)
TSLA  429.52
-16.39 (-3.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.